Mr. Diabetes® Named 'Hero' and Awarded $50,000 for Favorite Charity - Defeat Diabetes Foundation
MADEIRA BEACH, Fla., April 10, 2012 /PRNewswire/ -- The Tampa Bay Lightning Foundation, the philanthropic arm of the Tampa Bay Lighting National Hockey League team, awarded Andrew P. Mandell, known internationally as Mr.

Dart Health Coaching & Consulting Helps Individuals and Medical Professionals Manage Daily Diabetes Challenges
AUBURN, N.Y., April 2, 2012 /PRNewswire/ -- Health consultant and coach Michelle A. Dart () is using her expertise as a pediatric nurse practitioner and certified diabetes educator to provide guidance for people of all ages with Type 1 or Type 2 diabetes and their families as well as nurses involved with treating diabetes.

BYETTA® Approved for Use with Basal Insulin in Europe
SAN DIEGO and INDIANAPOLIS, March 23, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted marketing authorization to BYETTA® (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. "The marketing authorization for the use of BYETTA with basal insulin provides a new option for the many patients with type 2 diabetes who are not achieving treatment goals," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals.

Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhib
NEW YORK, March 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors an ...